Exicure Q2 FY26 net loss narrows 57% to $1.12 million; reports no revenue

• Exicure posted a net loss of USD 1.12 million, narrowing 57% from the prior-year quarter, while revenue was flat at no revenue.
• Operating loss narrowed 58% to USD 1.05 million as operating expenses fell 58% to USD 1.05 million.
• R&D expense dropped 81% to USD 174,000; general and administrative costs declined 41% to USD 889,000.
• Cash and cash equivalents fell to USD 1.7 million at June 30, 2026 from USD 3.7 million at Dec. 31, 2025; substantial doubt flagged on going concern.
• GPCR USA’s Phase 2 trial completed in January 2026; a USD 1 million milestone became payable in Q2 2026, expected to be settled in shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exicure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-352011), on August 14, 2026, and is solely responsible for the information contained therein.